ResMed, Inc. RMD recently introduced its AirCurve ... AirCurve 11 is a bilevel PAP device meant to improve comfort and compliance by giving higher pressure during inhalation and lower pressure ...

UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

ResMed on Tuesday announced that it has launched AirSense 11 in India. According to the company’s statement, it is the next-generation Continuous Positive Airway Pressure (CPAP) device designed ...

In the latest quarter, 5 analysts provided ratings for ResMed RMD, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how ...

Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Analyst Lyanne Harrison of Bank of America Securities reiterated a Buy rating on Resmed (RMD – Research Report), retaining the price target of ...

Analysts at Catapult Wealth are positive on sleep treatment company ResMed and think it could be an ASX 200 share to buy. Catapult Wealth's analysts have been pleased with ResMed's performance in ...